These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28932928)

  • 21. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
    Gupta N; Hanley MJ; Harvey RD; Badros A; Lipe B; Kukreti V; Berdeja J; Yang H; Hui AM; Qian M; Zhang X; Venkatakrishnan K; Chari A
    Br J Haematol; 2016 Sep; 174(5):748-59. PubMed ID: 27196567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
    Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
    Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
    Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Sanchorawala V; Palladini G; Kukreti V; Zonder JA; Cohen AD; Seldin DC; Dispenzieri A; Jaccard A; Schönland SO; Berg D; Yang H; Gupta N; Hui AM; Comenzo RL; Merlini G
    Blood; 2017 Aug; 130(5):597-605. PubMed ID: 28550039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 1 Mass Balance Study of
    Yu Y; Chung CH; Plotka A; Quinn K; Shi H; Pápai Z; Nguyen L; Wang D
    J Clin Pharmacol; 2019 Sep; 59(9):1195-1203. PubMed ID: 30964553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
    BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
    Machida M; Fukunaga S; Hara T
    Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.
    Calvo E; Reddy G; Boni V; García-Cañamaque L; Song T; Tjornelund J; Choi MR; Allen LF
    Invest New Drugs; 2016 Apr; 34(2):193-201. PubMed ID: 26769244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of absorption, distribution, metabolism, and excretion of [
    Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
    Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
    Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
    Kato S; Adashek JJ; Subbiah V; Fu S; Sun M; Nguyen L; Brown EJ; Yap TA; Karp DD; Piha-Paul SA; Hong DS
    Invest New Drugs; 2022 Feb; 40(1):99-105. PubMed ID: 34468905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and excretion of
    van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
    Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
    Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients.
    Poondru S; Chaves J; Yuen G; Parker B; Conklin E; Singh M; Nagata M; Gill S
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):829-37. PubMed ID: 26972330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
    Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
    Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.